July 30, 2025
IPSEN – Buy-back programme – Art 5 of MAR – Week 30 – 2025
Aggregated presentation by day and by marketStatement of transactions in own shares from July 21st to July 25th 2025 Name of…
Pharmaceuticals, Biotechnology and Life Sciences
Aggregated presentation by day and by marketStatement of transactions in own shares from July 21st to July 25th 2025 Name of…
KIGALI, Rwanda and SAN FRANCISCO and AUBAGNE, France, July 29, 2025 (GLOBE NEWSWIRE) — Bio Usawa Biotechnology, Ltd. (Bio Usawa),…
Proven efficacy across all three key markers of disease—68% reduction in proteinuria, stabilization of kidney function, and substantial clearance of…
CARLSBAD, Calif., July 28, 2025 (GLOBE NEWSWIRE) — Qualigen Therapeutics, Inc. (NASDAQ: QLGN) (the “Company”) received two different communications from…
Fiscal Year Net Revenue of $821 Million, $834 Million in Constant Currency, Strategic Decisions Impacted Revenue by $35 Million Q4…
NEW YORK, July 28, 2025 (GLOBE NEWSWIRE) — Cellectis (the “Company”) (Euronext Growth: ALCLS- NASDAQ: CLLS), a clinical-stage biotechnology company…
– Phase 1a clinical data in healthy participants presented for both ABI-5366 and ABI-1179, novel long-acting herpes simplex virus helicase-primase…
TORONTO, July 25, 2025 (GLOBE NEWSWIRE) — PharmAla Biotech Holdings Inc. (“PharmAla” or the “Company”) (CSE: MDMA) (OTC: MDXXF), a…
SAN DIEGO, July 25, 2025 (GLOBE NEWSWIRE) — Calidi Biotherapeutics, Inc. (“Calidi” or the “Company”) (NYSE American: CLDI), a clinical-stage…
DOVER, Del., July 25, 2025 (GLOBE NEWSWIRE) — Portage Biotech Inc. (“Portage” or the “Company”) (NASDAQ: PRTG), a clinical-stage immuno-oncology…